22 February 2024 0 7K Report

At present, the treatment direction of IGA nephropathy mainly focuses on targeted therapy of B cells and complement system, regulation of intestinal microbiome, SGLT2 inhibitor treatment, endothelin receptor antagonist treatment, etc. The treatment effect is always limited and cannot be carried out. Clinical cure can only provide remission and cannot achieve a state of never entering uremia. Can we change the direction and use other immune system diseases or immune system responses to achieve the ultimate goal of treating iga nephropathy? It is currently in a hypothetical state, and I hope there will be more Experts and scholars can verify the feasibility of this direction. If there are new developments or better suggestions, you can contact me.

More Jing Xue's questions See All
Similar questions and discussions